|Bid||65.50 x 3000|
|Ask||70.47 x 800|
|Day's Range||65.22 - 67.55|
|52 Week Range||37.36 - 81.22|
|Beta (3Y Monthly)||0.87|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 30, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||86.09|
Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as Exact Sciences Corporation (NASDAQ:EXAS), with a market capitalization of US$8.3b, rarely draw their attention from the investing Read More...
NEW YORK, Oct. 04, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Today, TG Therapeutics stock is trading at a price of $5.82, which is ~37.0% down from yesterday’s closing price of $9.25. The stock also hit a 52-week low of $5.70. TG Therapeutics had hit a 52-week high of $17.35 on March 9. Reason for the decline
Exact Sciences (EXAS) stock has reported a 67.1% rise in the last month, from $49.93 on August 10 to $75.99 on September 10. Its performance was mainly due to its collaboration with Pfizer (PFE) for the increasing adoption of Exact Sciences’ Cologuard non-invasive stool DNA test for colorectal cancer screening in the United States. According to the collaboration announced on August 22, Pfizer will actively participate in promoting Cologuard until 2021.
NEW YORK, NY / ACCESSWIRE / August 24, 2018 / U.S. markets plunged on Thursday following the release of the minutes from the latest Federal Reserve meeting, which called for an interest hike in September. ...
Exact Sciences (EXAS) reaches a co-promotion agreement with Pfizer to commercialize its non-invasive screening test for colorectal cancer, Cologuard. The stock rallies following this news.
NEW YORK, NY / ACCESSWIRE / August 23, 2018 / Exact Sciences made headlines on Wednesday, announcing an agreement with Pfizer to share marketing expenses and to co-promote the company’s Colorguard colorectal ...
Exact Sciences doesn’t do glamorous work, but on Wednesday its shareholders got beautiful results. The health-care company announced a collaboration deal with Pfizer to market its signature product, Cologuard, a stool DNA screening test for colorectal cancer.
On August 22, Exact Sciences (EXAS) is trading at a stock price of $62.95, which represents ~25.78% growth from the close of $50.05 on August 21.
NEW YORK, NY / ACCESSWIRE / August 3, 2018 / DexCom and Exact Sciences Corporation went in separate directions after reporting second quarter results. DexCom exploded and hit a new high after reporting an earnings beat while Exact Sciences slipped almost 13% after missing its revenue expectations. DexCom, Inc. shares closed up 30.65% on nearly 7 million shares traded.
Jim Cramer shares his take on callers' favorite stocks at lightning speed, including an airline play that could soon fly higher.
Stock futures fell on U.S.-China trade war fears: Tesla stock soared on cash levels and profitability plans, Wynn Resorts and Exact Sciences also moved on earnings.
The high-flying maker of Cologuard DNA tests fails to deliver in Q2 on sky-high revenue growth expectations.
Stock Research Monitor: CGIX, CHEK, and EXAS LONDON, UK / ACCESSWIRE / July 12, 2018 / If you want a free Stock Review on DXCM sign up now at www.wallstequities.com/registration . Today's research on WallStEquities.com ...
Demand for its colon cancer screening solution continues to drive sales higher even as the company invests in next-generation screening.
J. P. Morgan analysts recommended investors continue to overweight small-cap stocks, seeing them as shielded from the escalating risk of a trade war and U.S. dollar volatility
Exact Sciences broke out to a record high Wednesday after the biotech showed its newest blood test could detect curable liver cancer in 91% of patients studied.